Back to today’s briefing

Story perspectives

Wegovy Sales Skyrocket 19.9 Billion; Shares Surge 5.3%

2/6/2025

34 3

Summary

Story summary

Novo Nordisk's Wegovy sales soared to an impressive 19.9 billion kroner in Q4 2024, doubling from previous figures. While the company braces for a slower growth rate of 16% to 24% in 2025 amid fierce competition from Eli Lilly, shares surged 5.3% after the company reported earnings that surpassed expectations.

History

Historical Context

Novo Nordisk's Wegovy sales surge reflects a broader trend in the pharmaceutical industry, where blockbuster drugs like Humira and Zyprexa previously dominated. As competition intensifies, companies must innovate and adapt, reminiscent of past shifts when new therapies disrupted established market leaders, reshaping patient care and revenue streams.

1 of 2

Story summary

Novo Nordisk's Wegovy sales soared to an impressive 19.9 billion kroner in Q4 2024, doubling from previous figures. While the company braces for a slower growth rate of 16% to 24% in 2025 amid fierce competition from Eli Lilly, shares surged 5.3% after the company reported earnings that surpassed expectations.

1 / 2